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Background: Cardiovascular diseases (CVDs) are one of the leading causes of death and disability in the world.
Over 80% of CVD deaths take place in low-and middle-income countries. One-third of the population aged above
40 years suffers from Hypertension (HTN) and this is largely unreported as there is no registry for CVDs. No
guidelines are available for use in health care facilities, especially private health facilities where practice among GPs
varies considerably. We aim to conduct a Cluster Randomized Controlled trial delivering a quality HTN-CVD care
package at strengthened private health facilities as compared to current practice at private health facilities.
Methods/Design: A pragmatic cluster randomized trial, with qualitative and economic studies, will be conducted
in Sargodha district of Punjab, Pakistan, from January 2012 to December 2016. At least 912 hypertensives will be
registered in the two arms, six clusters per arm. The proposed cluster randomized controlled trial will evaluate the
effects of delivering quality HTN-CVD care, through enabled private health care facilities, to achieve better case
registration, adherence and hypertension control also blood glucose and serum cholesterol control. The trial will be
conducted through the doctors and paramedics at private health facilities. Main outcomes are mean difference in
Systolic blood pressure among the two arms. Secondary outcomes are mean change in total serum cholesterol
levels and mean change in glycaemic control achieved in the adult hypertensive patients. Individual and Cluster
level analysis will be done according to intention-to-treat.
Discussion: Due to the high burden of disease where 1 in 3 individuals aged above 45 suffers from hypertension,
topped with the fact that there is a dearth of a set of available, standardised guidelines for management, the
disease is constantly on a hike in Pakistan. The government has made no effort to issue a set of guidelines adapted
specifically for our population and this becomes more of a problem when managing CVD in urban population
through private practitioners whose practices vary widely.If our set of context sensitive guidelines show an
effectiveness in the proposed intervention districts it will be replicated in other such settings.
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Burden of CVD in Pakistan
The WHO report on Global atlas on cardiovascular
disease prevention and control states that cardiovascular
diseases (CVDs) are the leading causes of death and dis-
ability in the world. Over 80% of CVD deaths take place
in low-and middle-income countries [1]. Despite convin-
cing evidence that lowering of blood pressure decreases
cardiovascular morbidity and mortality, the control of
hypertension has been poor in developing countries due
to a multitude of reasons.
According to National Health Survey Pakistan (NHSP)
hypertension was shown to affect 18% of adults
aged >15 years and around 33% of adults above 45 years
[2]. In Pakistan there is a lack of adequate data on the
CVD disease burden as well as the risk factors involved.
Urban health and facilities available
A study done in urban settings (by Jafari et al.) found
that 27.6%and 39.3% of hypertensive patients suffer from
concomitant diabetes and hypercholesterolemia respec-
tively, whereas 45.3% are smokers [3].
In urban areas, the availability and quality of the first
level care public facilities is not adequate. This makes
private clinics/ small hospitals an alternate “choice” for
the first level care in urban areas. However, in the ab-
sence of a regulatory and/or partnership mechanism, the
care delivery practices vary widely.
Public–private mix models in Pakistan
In Pakistan two main models of public-private mix
(PPM) emerged so far are the “social franchise” and the
“district-led partnership” models. The variants of social
franchise model (e.g. greenstar, MSS model) have been
tested and found workable for delivering reproductive
health and communicable disease care interventions in
selected urban areas.
The district-led partnership model has been developed
through an extensive and systematic exercise in Pakistan.
The exercise included: a) strategic framework and inter-
vention design; b) guidelines and products for planning,
implementing and monitoring partnership interventions;
c) piloting and evaluation of guidelines and products;
and d) scaling-up of the refined modela for TB, malaria,
and more recently MDR-TB interventions.
Involvement of the association
The Association is a not for profit company with vast
experience of working in TB, lung health, reproductive
health and cardiovascular diseases. The Association and
Nuffield Institute have been the lead program technical
partners for developing the district-led partnership
model in Pakistan. Currently, the Association is res-
ponsible for implementing public-private partnershipinterventions in: 18 districts for DOTS and MDR-TB
(TGF R-9), and 2 districts for RBM (TGF Round 7 and
10). This valuable experience and strong field presence
will help the Association to implement the proposed
CVD-HTN intervention in 1-2 of the districts with an
ongoing public-private partnership for communicable
disease control.
Rationale
The proposed implementation research is to develop
and evaluate a model of delivering CVD-HTN care
package through a network of private clinics, already
engaged in communicable disease control activities. The
care delivery dimensions that need further attention
include: chronicity of disease requiring relatively long-
term liaison between patient and care provider, higher
prevalence, combination of drugs and lifestyle interven-
tions, and poorly defined management support arrange-
ments at district level.
The CVD-HTN care delivery modalities and products
are required for ensuring quality and planning ex-
pansion. The proposed exercise is to develop and eva-
luate an intervention for delivering quality CVD-HTN
care through enabled private health facilities. The set of
implementation products may include: case management
desk guide, training module, recording/reporting and
monitoring instruments, and communication tool. These
products will cover the technical and operational aspects
of managing cases i.e. screening, diagnosis, prescription,
education, follow-up etc.
Aim
The aim is to enhance the delivery of quality CVD-HTN
care through private health facilities in urban settings.
The conditions to be covered in the care package include:
hypertension, type 2 diabetes, and hypercholesteremia.
Primary objective
To compare the mean change in systolic blood pressure
(10 mmHg) in adult patients (>25 years) receiving en-
hanced CVD-HTN care package with the mean change
in systolic blood pressure (5 mmHg) for those receiving
routine care at the private facilities in Punjab.
Secondary objectives
 To compare the mean difference in systolic blood
pressure (at least 6 mmHg) due to the intervention.
 To compare the mean change in total serum
cholesterol (at least 4 mg/dl decrease) achieved in
the adult hypertensive patients.
 To compare the mean change in glycaemic control
in the adult type 2 diabetes patients (among
registered hypertensive cases) receiving enhanced
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comparison with the mean change for those
receiving routine CVD-HTN care at the private
health facilities(1%change in HbA1c).
 To compare the tobacco cessation rate in
intervention arm (41%) and control arm (8%).
 Record adverse events of Cardiovascular disease
(MI, angina) and cerebro-vascular disease (stroke)
among the two arms of the study.
 To conduct incremental cost effectiveness analysis
of managing adult hypertensive patients with or
without associated conditions (Type 2 diabetes and
hypercholesterolemia) at private care facilities in
Punjab, Pakistan.
Research question
 How effective and feasible is to deliver and manage
quality care for the control of selected cardiovascular
diseases (i.e. hypertension, type-II diabetes, and hyper-
cholesteremia) in adults (i.e. > 25 years), through
enabled private health facilities as compared to
current practice, in urban settings?
The control of selected cardiovascular diseases will be
assessed by measuring change in blood pressure, blood
glucose, and serum cholesterol.
Hypothesis
 The enabling of private health facilities for
cardiovascular disease intervention for adult
hypertensive patients will improve the control of
hypertension by decreasing mean systolic BP by at
least 6 mm Hg.
 The enabling of private health facilities for
cardiovascular disease intervention for adult
hypertensive patients will improve the control of
Blood glucose (HbA1C < 7.5%) and serum
cholesterol (<200 mg/dl) by at least 15%
(as compared to the current practice).
Methods/Design
Study design
A pragmatic parallel arms cluster randomized controlled
trial (c RCT) with two arms will be conducted from
January 2012 to December 2016 with a duration of
60 months.
The proposed cluster randomized controlled trial will
evaluate the effects of delivering quality HTN-CVD care,
through enabled private health care facilities, to achieve
better adherence and hypertension control also blood
glucose and serum cholesterol control. The trial will
have two arms (Figure 1).Interventions
Intervention arm
Quality care will be delivered to adult hypertension pa-
tients, through enabled private healthcare facilities. The
inputs for delivering quality care at enabled facilities will
include: a) context sensitive operational guidelinesb, b)
supplement equipment and communication, c) training
and supervisory support, d) patient education materials.
The care delivery dimensions to be addressed will
include: a) enhanced screening and diagnosis, b) stan-
dardized prescription, c) interactive education of patient
and family, d) follow-up and adherence, e) recording,
reporting and monitoring, f ) referral linkage with
respective district hospital, g) district health office
engagement and support, and h) technical support for
in-country research uptake.
Control arm
The control for comparison is the current care practices
(for hypertension and associated conditions) at the
private health care facilities. The only addition will be
a) enhanced screening and diagnosis, b) introduction of
HTN-CVD register for collecting core data set on
patients attending these control facilities. In ‘current
practice’, each practitioner manages HTN-CVD cases, as
per his/her self-determined regimen and without refe-
rence to any specific guidelines and/or tools.
The health staff at a facility will offer the same care pac-
kage to all its HTN-CVD cases, regardless of their social
strata and other preferences. This will reduce the chances
of intra-cluster contamination as well as strengthen and
simplify the implementation of prospective evaluation. All
trial patients will be asked to arrange their prescribed
drugs, so that the trial reflects the real life practice in
private health care delivery system.
Study setting
Sargodha is the tentatively proposed district for im-
plementing the research. About one-third of the district
population lives in urban areas (i.e. 1 million out of
3.1 million). About 38% of the urban population is above
25 years of age (i.e. 380,000), and about a quarter of
these are expected to be hypertensives (95,000).
In Sargodha, the Association has actively been engaged
in supporting the implementation of various disease con-
trol interventions through district health systems. These
include communicable diseases like TB-DOTS and sexu-
ally transmitted infection (STI) control, tobacco cessation,
public-private partnership, advocacy-communication and
social mobilization for disease control, drug manage-
ment enhancement etc. This experience-based under-
standing and trust with the district health office would
help partners to implement the proposed public-private
partnership innovation.
Analysis according to Intention to treat
Study Population





(n=6 clusters, 76 patients/cluster)
Trial Arm 2
Current Practice
(n=6 clusters, 76 patients /cluster)
Outcome assessment
Blood Hypertension control - the mean change in systolic blood pressure (i.e. change of mean blood pressure at 15 months of follow-up 
compared to the baseline at registration) 
Secondary outcomes include:
Glycaemic control – the mean change in HbA1c (i.e. change of mean HbA1c at 15 months of follow-up compared to the baseline at 
registration) 
Cholesterol control – the change in serum cholesterol at 15 months of follow-up compared to the baseline at registration 
Smoking cessation – the proportion of sustained quit at 15 months of follow-up, as validated through carbon mono oxide concentration in 
exhaled air
Study sample
Private Health Facilities enabled for 
Hypertension-CVD trial
(N=12)
Figure 1 Flow chart of study.
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In these two districts, 12 private health facilities will be
selected into the trial.Identifying participants
A group of private facilities has already been selected for
TB-PPM intervention in the district. These facilities have
been selected on basis of objective functioning and wil-
lingness criteria. The private facilities for HTN-CVD
trial will be identified from the already functioning faci-
lities in the district.
The individuals attending the outpatients will be iden-
tified and screened for HTN and subsequently for type 2diabetes, hypercholesterolemia and smoking, as per
agreed care delivery guidelines.
Approaching participants
The eligible facilities will be approached through district
health office for possible inclusion in the trial. Through re-
spective health facility, communal consent will be ar-
ranged from the respective catchment populations. The
facilities where both staff and the catchment population
consent to participate will be selected in the trial.
Inclusion/exclusion criteria
Among these private facilities ,all newly diagnosed
hypertensive (systolic blood pressure >140 mm Hg,
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patients aged 25 years or more from the catchment
population of the respective facility will be included,
after an informed consent. The patients to be excluded
from the trial are: a) pregnant women, b) persons with
advanced chronic disease, c) person with conditions that
cause secondary hypertension, d) person with known
history of hypertension and/or CVD treatment in the
past, e) person not likely to stay in the area for the re-
quired follow-up period of 15 months.
Patients who are pregnant and have hypertension will
be referred to a gynecologist, patients with advanced
chronic disease to a general medical practitioner, and
those with a known history of hypertension and/or CVD
treatment in the past will be referred to a cardiologist.
Only patients who are new cases of hypertension are in-
cluded in the trial. People with known hypertension are
excluded from the trial as they would already be on
some sort of antihypertensive drug regimen which may
mask the effects of our intervention.
Recruiting participants
The eligible for inclusion patients will be informed and
offered to participate (see inclusion/ exclusion criteria
above). The patient is recruited only if he/she consents
to participate.
Once recruited, each patient in the:
– control arm will be offered standardized diagnosis
and care as per current practice, whereas
intervention arm will be offered an enhanced HTN-
CVD care including standardized diagnosis,
prescription, follow-up, and monitoring.
– intervention arm will also be educated on life style
modifications recommended for the individual,
whereas control arm patients will receive
information brochure.
– both arms will be asked to arrange the prescribed
medicine through their own sources. However,
access to baseline BP, HbA1c, cholesterol
examination will be facilitated, for both arms,
through trial resources.
Both arms will be requested to adhere to the treatment
protocols.
Data management procedures
Most of the data will be collected as a part of the care
delivery process by doctors and paramedics on the
‘CVD card’. Other data related especially to trial will be
recorded on the ‘trial registration form (TRF). Research
assistant (RA) will visit the identified Lab on monthly
basis and will collect test results. RA will visit each
centre on monthly basis and will i) check each TRF forcompleteness and correctness, and those found with
missing data will be acted upon accordingly. ii) correlate
the Lab results with entries on TRF iii) check for drugs
and supplies and reimburse for gaps. RA will send a
copy of TRF and Lab test results to the central office i)
at test one i.e. baseline ii) at test two i.e. final outcome,
for data entry, cleaning and analysis.
Data confidentiality and data entry
Each form will be sent as mentioned above by a regis-
tered courier service in a sealed envelope. The forms will
be kept under lock and key in the central ASD office
with only the PI and project coordinator having access
to them. Data entry will be done twice by two indepen-
dent data entry operators to minimize typing errors.
Data will be entered on SPSS 20.
Statistical considerations
Sample size
A total of twelve clustersc (i.e. six clusters in each trial
arm) will be included in the study, with a minimum of
76 patients recruitment in each cluster and a total of
912 patients in the trial. The assumptions are: a) an
intra-class correlation coefficient (ICC) of 0.02, b) design
effect of 2.5 [4], c) and standard deviation of blood
pressure as 11 mm [5] d) lost to follow-up of 25%. This
sample size will give 94% power using 5% level of signifi-
cance for detecting an assumed difference in the mean
change of systolic blood pressure of 6 mm Hg between
the intervention and the control arm [6,7].
For a sub group analysis of hypertensive patients with
concomitant type-II diabetes, the main assumption is
that 27.6% of the recruited hypertensive will have type-
II diabetes i.e. 21 patients out of 76 hypertensive re-
cruited at each clinic will be have diabetes [3]. The
proposed sample size will give 86% power using 5% level
of significance for detecting an assumed difference in
mean change of HbA1c of 1% [8,9] between the inter-
vention and the control arms. The assumed standard
deviation of HbA1c is 2% [10], and intra-cluster cor-
relation is 0.02 [6,7].
For a sub group analysis of hypertensive patients with
concomitant hyper-cholesteremia, the main assumption is
that 39.3% of the recruited hypertensive will have hyper-
cholesteremia i.e. 30 patients out of 76 hypertensive
recruited at each clinic will be have hyper-cholesteremia
[3]. The proposed sample size will give 100% power using
5% level of significance for detecting an assumed dif-
ference of 4.9 mg/dl [11] between the group means. The
assumed standard deviation is 2.9 mg/dl [11], and intra-
cluster correlation is 0.02 [6,7].
For a sub group analysis those hypertensive patients
who smoke, the main assumption is that 34.5% of the
recruited hypertensive will be tobacco smokers i.e. 27
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smokers [3]. The proposed sample size will give 100%
power using 5% significance level for detecting a differ-
ence between the group proportions of 0.33 when the
intra-cluster correlation is 0.02 [6,7].
Planned analysis
The results in each cluster would be analyzed on the
basis of “intention to treat”. This means the quality of
care and service utilization outcomes of each patient
will be counted in the intervention for the cluster, re-
gardless of their actually accepting or availing the of-
fered services.
Planned statistical tests
Cluster and individual level analysis will be done on
SPPS version 17. Histograms will be made for the con-
tinuous variables e.g. age, systolic blood pressure, dia-
stolic blood pressure, fasting blood glucose, HbA1c etc.
Descriptive statistics will be computed: proportion for
categorical variables, mean and standard deviation for
continuous variables having normal distribution, median
and inter quartile range for continuous variables having
skewed distribution.
a. Difference of mean systolic blood pressure at
baseline and then at 15 months of follow up
between the intervention and the control arm will
be measured by independent t-test. Difference of
mean systolic blood pressure at baseline and at
15 months of follow up in the intervention arm/
control arm will be measured by the paired sample
t-test. Mean change of systolic blood pressure
between intervention and the control arm will be
measured by t-test. P-value of < 0.05 will be
considered significant.
b. Difference of mean HBA1c at baseline and then at
15 months of follow up between the intervention
and the control arm will be measured by
independent t-test. Difference of mean HBA1c at
baseline and at 15 months of follow up in the
intervention arm/control arm will be measured by
the paired sample t-test. Mean change of HBA1c
between intervention and the control arm will be
measured by t-test. P-value of < 0.05 will be
considered significant.
c. Difference of mean total cholesterol levels at
baseline and then at 15 months of follow up
between the intervention and the control arm will
be measured by independent t-test. Difference of
mean total cholesterol levels at baseline and at
15 months of follow up in the intervention arm/
control arm will be measured by the paired sample
t-test. Mean change of total cholesterol levelsbetween intervention and the control arm will be
measured by t-test. P-value of < 0.05 will be
considered significant.
d. Proportions of adult Type 2 diabetes patients having
htn control (<140/90) in the two arms will be
compared by conducting chi-square test. P-value
of < 0.05 will be considered significant.
e. Residual confounding will be taken care of by
multivariable regression (MLR)analysis. Strartified
MLR will be done with the different groups of
medications being as different strata eg, Beta
blockers, ACE inhibitors, ARBs, Calcium channel
blockers etc. being as different strata. Results will be
presented in a stratified analysis. This will take care
of confounding my different effects on BP from
different groups of anti hypertensive drugs.
f. Incremental cost and effect will be calculated for the
intervention and the control arms and subsequently
cost: effect ratio will be calculated.
Phases of the trial
The trial will have the following three phases: Refer to
Figure 2.
1) Inception & piloting phase. The main purpose of the
two-year phase is to develop, pilot and refine the care
delivery guidelines/ materials and trial design/
protocols before embarking upon the trial registration.
– The piloting experiences and results will enable
the research team to:
– Assess the feasibility and acceptability, and then
accordingly modifythe process for health facility
selection (i.e. facility assessment, providers’ and
communal consent for the trial etc.) and
management support (logistic supplement,
reporting, monitoring etc.)
– Assess the feasibility and acceptability, and then
accordingly modifythe case management
guidelines i.e. diagnosis, treatment, record
keeping, follow-up etc.
– Assess the feasibility and robustness of the
research protocols, then accordingly modify, the
protocols for case inclusion/ exclusion,
recruitment rate, and periodic assessment
(research related).
– Revisit the assumed proportion of diabetics,
dyslipidemic and smoker patients among adult
hypertensive patients in local context.
– Revisit the assumptions about sample size
calculation to meet the power of the study such
as mean change (± standard deviation) in systolic
blood pressure, glycaemic and cholesterol control,
and tobacco cessation between intervention and
control arms.
Figure 2 Phases of the trial.
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statistical methods to analyze the trial data.
– The qualitative interviews with providers
(± patients) for assessing the feasibility during the
trial piloting will also be adapted subsequently for
the trial assessment. In short the trial piloting will
inform the decision to implement the trial to get
optimal results and valid evidence.
2) Trial Implementation phase
– In the first 03 months of the trial implementation
phase, the following arrangements will be made
before start registering cases in the trial.
– Refine the case management guidelines/ materials
Assess and shortlist the health facilities for
possible inclusion in the trial. Randomization :
The ASD central trial unit, under the supervision
of Trial Steering Committee, will then randomize
the facilities into two trial arms. Randomization
preformed will be simple randomization. Each
participating facility (cluster) will be given a
unique ID which the investigators will be blinded
to.12 different sheets of paper will be taken and
the unique ID of each cluster will be written on
the paper, which will be folded and sealed into an
envelop.12 such sealed envelopes will be made.Then by a simple procedure, 6 sealed envelopes
will be selected by hand picking them randomly
from the pile of 12 sealed envelopes.6 will be
hand picked for the intervention arm and 6
sealed envelopes for the control arm. The
Steering committee will consist of a director, two
people from ASD and two people from
in-country (PMRC) and international partners
(WHO).
At least two doctors and two paramedics from each
participating facility will be trained. The intervention
facility staff will be trained on enhanced case
management guidelines and materials including
recording reporting and enhanced follow-up and
referral, whereas the control facility staff will be
trained only to register and report, use patient
education brochure, and access HbA1c and
cholesterol testing for trial patients.
– In the next 06 months of the trial
implementation phase, the patients will be
registered and enrolled in the trial, as per agreed
protocols. During the period the baseline
hypertension measurement will be validated by
an external expert examination, kept blind to the
trial arm as well as any previous measurements.
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intervention arm will include: case management
desk-guide for patient care, flip chart and brochure
for patient education, mobile link for late patient
retrieval, referral for advanced care (if needed),
regular monitoring and support.
Once the required number of trial patients is
enrolled in the trial, the subsequent patients will
receive HTN-CVD and associated care from the
respective facility (as per prevailing case
management protocols i.e. either intervention or
control) but their results will not be included in the
trial evaluation.
The research team will closely monitor the inclusion
and exclusion of trial patients, mainly to identify and
respond to any deviation from the research
protocols and/or case management processes.
– In the next 15 months of the trial
implementation phase, the registered trial
patients will be followed-up to measure the
outcomes.
– All patients will pay for the case management
services, as per facility protocols. However, the
measurement of hypertension, HbA1c, serum
cholesterol and carbon mono oxide in exhaled air
will be paid from the project sources (as these
measurements are being made solely for the trial
evaluation). The referral to district headquarter
hospital, as required, for specialist consultation
(e.g. cardiology, ophthalmic examination, renal
assessment, drug side effect) will be managed as
per agreed guidelines for intervention arm and as
per current routine in the control arm. The
specialist facility will be encouraged to refer back
patients to the respective referring facility, after
providing the requested specialist care.
– The case management record on each patient will
be maintained in the chronic disease register
(to be developed and introduced through the trial
inputs). The chronic disease register at each
facility will provide the data for detailed analysis
on case management experiences in the two trial
arms.
– The modalities for periodically monitoring the
participating facilities (including reviewing
records and collecting reports) will be developed
during the initial development phase (see section
12 below). The research team will ensure that
each participating facility is monitored as per
guidelines agreed for the respective facility
(i.e. intervention and control).
– The research team will also supplement the
logistic inputs at the participating facilities. This
includes maintenance of BP apparatus,glucometer and supplies, print materials etc. at
the participating facilities.
3) Intervention Evaluation and Research Take-up phase
Costing study
A costing analysis will be designed and conducted to in-
form programmatic decisions by managers and policy
makers for possible scaling-up in other districts with on-
going PPM for communicable disease control. The min-
imal is the incremental cost effectiveness ratio (ICER)
analysis of the provider cost (i.e. health department and
private facility). The ICER will focus mainly on cost of
additional inputs (training, materials, monitoring etc.) at
private facility level to achieve the outcomes. This ana-
lysis is more relevant for the health department decision
makers to consider scaling-up the intervention. The
main source of cost data will be records and key inform-
ant interviews. We will also explore the possibility of
covering, to an extent possible, the patient perspective
to the care for HTN and associated conditions. This
might involve surveying the registered patients for cost-
ing and coping experiences.
Explanatory qualitative study
Qualitative interviews with selected care providers (6),
and patients (12)d will help to better understand the ex-
periences. A qualified anthropologist, with help of other
members, will develop the interview schedules and con-
duct the semi-structured interviews with various indivi-
dual categories of interest. The study would collect data
on a range of social, economic, service access and quality
etc. factors from care providers as well as patients and
their families to assess the social and administrative
feasibility of said interventions in the programme con-
text and inform refinements before scaling-up to other
parts of the country.
Dissemination
The results/experiences and products of research will
also be shared with wider stakeholders through: a) exis-
ting partner networks (e.g. COMDIS,), b) presentations
at national and international conferences (e.g. White
Ribbon Alliance, World Federation of Public Health
Associations), and c) access to resource centers/web-
sites more widely used e.g. WHO.
The scientific papers, based on results of the trial and
associated studies, will be submitted to international and
national peer-reviewed journals. The potential journals
to target includes: BMC cardiovascular disease, Lancet,
British Medical Journal, WHO Bulletin, BMC Imple-
mentation Science-process evaluation study(s); Health
Policy and Planning, Reproductive Health Matters-social
science (qualitative studies).
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Current situation
Due to the high burden of disease where 1 in 3 indivi-
duals aged above 45 suffers from hypertension, topped
with the fact that there is a dearth of a set of available,
standardised guidelines for management, the disease is
constantly on a hike in Pakistan. The government has
made no effort to issue a set of guidelines adapted
specifically for our population and this becomes more of
a problem when managing CVD in urban population
through private practitioners whose practices vary
widely. If our set of context sensitive guidelines show an
effectiveness in the proposed intervention districts, the 6
facilities in control arm will also be enabled for imple-
menting the enhanced HTN-CVD care guidelines and
materials. The enabling primarily will include staff train-
ing, guidelines and materials and monitoring support.
Consultation with selected provincial health department
staff will be conducted for their considering and plan-
ning (if possible) the scaling-up of HTN-CVD PPM
intervention in other 31 districts of Punjab where PPM
for communicable disease (TB) control is already being
implemented through GFATM grant.
Addressing bias, error and limitations
Comparing the socio-demographic and health services
profiles of the private facilities does not indicate any sig-
nificant difference that can potentially lead to differences
in care seeking behavior and/or quality of service. The
proposed cluster randomization is expected to address
the potential selection bias across the two trial arms.
The process of equal screening and diagnosing training
in both arms will lead to similar disease intensity pa-
tients being recruited in both arms. Although similar
training of health professionals in both arms in regards
to better screening this will eliminate selection bias, it
will lead to a inability to measure ‘case detection rate’
due to better screening.
The lack of masking (blinding) could introduce bias
through two routes i.e. “incorrect measurement” and
“leakage” from one group to another. There was a pos-
sibility of incorrect measurement of “blood pressure out-
comes” by the facility doctor, who is aware of the
intervention allocation. This possibility of measurement
bias will be reduced through an unrelated external BP
monitoring doctor who is unaware of the intervention
allocation. Contamination across clusters is prevented by
keeping a minimum distance between clusters.
The proposed randomization does not allow asking
and responding to individual patient preferences. So the
trial will not answer the question what would happen if
health services are able to offer intervention according
to individually tailored patient needs/ convenience. Fur-
ther work will be needed to test the approaches sensitiveto individual preferences, in the local programme
setting.
The proposed method of randomization, ie concealed
simple randomization has its own limitations. This method
does not address the balance of baseline covariates. An
alternative approach could have been addresses the need
to control and balance the influence of covariates by using
stratified randomization. This method can be used to
achieve balance among groups in terms of baseline charac-
teristics (covariates) of health facilities based on socio
demographics of catchment population they feed into, size
of health facility, patient load etc. Different strata /blocks
of health facilities may have been made and then simple
randomization done in each strata to achieve a balance of
covarites. This could have minimized the biased that
simple randomization does not address.
Ethical considerations
The proposed study design, i.e. a randomized controlled
trial, is considered best for a prospective comparison of
two or more options or interventions. The relevant details
(e.g. selection of study and control population, sampling
technique and sample size, statistical methods etc.) have
carefully been considered to ensure valid measurements.
The endorsement of EDO (H), after explaining the
trial significance and methods, will be obtained. Then a
survey of eligible private health facilities will form the
basis for selection of well functioning and willing to par-
ticipate health facilities (i.e. consent to participate in the
trial). At each selected health facility communal consent
(from the respective catchment population) will be
obtained, by inviting an agreed group of key community
leaders. The facilities where communities consent to
participate will then be randomized into two trial arms.
The proposed process for seeking consent from the pri-
vate providers and respective communities is considered
ethical for the proposed cluster randomised controlled
trial.
The selection of current practice as a control arm is
also considered ethically acceptable. As there is no
existing evidence for an association between the pro-
posed interventions and better outcomes, the cluster
randomization into trial arms is considered justified. No
participant will be subjected to an additional burden or
a potentially coercive influence, or deprived of any care
that he/she would ordinarily receive. The outcome mea-
surement will be based on an objective and quality as-
sured data, gathered during the care delivery process.
There are no apparent issues related with confidentiality
of information about individual client in the trial.
The University of Leeds Research Ethics Committee,
granted the trial ethical approval on 20 March 2012, ref:
HSLTLM11026. National Bioethics Committee (NBC)
Pakistan has granted ethical approval for the proposed
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http://www.biomedcentral.com/1471-2261/13/76project on 30 April 2012, ref: NBC:89 The trial has also
been registered with the Current Controlled Trials
ISRCTN34381594.
Endnotes
aGFATM Rounds 7 and 10 for malaria, and Rounds 6,
8 and 9 for TB and MDR-TB care interventions.
bOperational guidelines, training materials and commu-
nication materials will be developed to deliver care for the
selected non-communicable conditions. Guidelines in
draft available, Public-private partnership in Cardiovascu-
lar Disease & Hypertension, cited from http://asd.com.pk/
CVD%20Guidelines/CVD%20deskguide%20(intervention
%20arm).pdf.
cA cluster is a private health care facility with its
catchment population.
d6men–3 un/successful from urban localities, and
same for women.
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